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High serum uric acid levels elevate pro-inflammatory–state gout crystal arthropathy and place individuals at high risk
for cardiovascular morbidity and mortality. Genome-wide scans in the genetically isolated Sardinian population
identified variants associated with serum uric acid levels as a quantitative trait. They mapped within GLUT9,a
Chromosome 4 glucose transporter gene predominantly expressed in liver and kidney. SNP rs6855911 showed the
strongest association (p ¼ 1.84 3 10
 16), along with eight others (p ¼ 7.75 3 10
 16 to 6.05 3 10
 11). Individuals
homozygous for the rare allele of rs6855911 (minor allele frequency ¼ 0.26) had 0.6 mg/dl less uric acid than those
homozygous for the common allele; the results were replicated in an unrelated cohort from Tuscany. Our results
suggest that polymorphisms in GLUT9 could affect glucose metabolism and uric acid synthesis and/or renal
reabsorption, influencing serum uric acid levels over a wide range of values.
Citation: Li S, Sanna S, Maschio A, Busonero F, Usala G, et al. (2007) The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet 3(11):
e194. doi:10.1371/journal.pgen.0030194
Introduction
Serum uric acid (UA) levels are frequently elevated in
conjunction with several disorders, including obesity, hyper-
lipidemia, atherosclerosis, and hyperinsulinemia [1]. Most
widely discussed have been ﬁndings of high serum UA in
individuals at risk of cardiovascular disease [2,3]. High UA
levels are causal in gout crystal arthropathy, and according to
some authors, are associated with a negative cardiovascular
risk proﬁle. Elevated UA is a risk factor for all-cause and
cardiovascular mortality in patients with prevalent cardio-
vascular disease, and an important prognostic factor in
hypertension.
Identifying factors that affect UA levels could help our
understanding of their role in pathology, improve clinical
decisions about whether to treat moderate hyperuricemia
[4,5], and help identify new targets for intervention aimed at
managing undesirably high UA levels. UA levels in humans
are generally higher than in other species because the gene
for the primary enzyme that transforms UA in other species,
uricase, is inactivated. Consequently, UA levels are deter-
mined by the balance between the production of UA through
purine catabolism (the two important contributors being
dietary purine levels and purines released from the DNA and
RNA of damaged cells) and the rate of excretion/reabsorption
in the kidney and intestine.
Several metabolic defects that may increase serum UA
levels have been described. Changes in the level of UA
synthesis can result from mutations or variation in activity of
enzymes involved in purine metabolism. In one relevant
instance, a microRNA has been reported that seems to
modulate the synthesis of UA through its repression of
phosphoribosyl pyrophosphate synthetase 1 [6]. Tissue
ischemia can also stimulate UA production by the upregula-
tion of xanthine oxidase. The alternative route to increased
UA levels is a decline in UA clearance in the kidney. The
urate/anion transporter [7] is highly expressed in the
proximal kidney tubule, and genetic variants in the genes
that code for the transporter may contribute to hyper-
uricemia [8].
In an attempt to discriminate genetic factors affecting UA
levels, we scanned the genome with a panel of 362,129 single
nucleotide polymorphisms (SNPs) in 4,305 Sardinian individ-
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glucose transporter gene, GLUT9, and UA levels. We also
show the association is conﬁrmed in an independent
population.
Results
UA levels and genotypes were assessed for a cohort of
individuals from Sardinia (see Materials and Methods). Using
a Bonferroni threshold of 1.3 3 10
 7 (0.05/362,129), we
selected 38 SNPs potentially associated with UA levels.
Unexpectedly, rather than identifying variants in purine
catabolism or in the urate transporter, the scan pointed to
GLUT9 [9] on Chromosome 4 (Figure 1; Table S1). All SNPs
exceeding the Bonferroni signiﬁcance threshold map to the
region that encodes this Class II glucose transporter [9]. The
rare allele ‘‘G’’ of the top ranked SNP rs6855911 has an effect
size of  0.317 mg/dl, with a more marked effect in women
than in men (Table 1). Figure 2 shows the contributions of the
two alleles of the SNP in homozygotes and heterozygotes.
Their effect is observed across the full range of UA values.
The strongest observed association of SNP rs6855911 and
distribution of the SNPs in linkage disequilibrium are shown
in Figure 3, along with the comparative linkage disequili-
brium patterns in the HapMap Utah residents with ancestry
from northern and western Europe (CEU) and Yoruba in
Ibadan, Nigeria (YRI) samples.
In a sequential analysis in which we selected the best SNP
for each trait and then conditioned on it to successively select
the next best SNP, a marker in the adjacent gene, WDR1, was
selected at the second round, meaning that its signal is—at
least in part—statistically independent from rs6855911 (Table
2). These results can support either the presence of multiple
variants in the same region or reﬂect different degrees of
linkage disequilibrium with a causal SNP that remains to be
identiﬁed.
The only other gene showing a cluster of SNPs associated
with UA levels—though at far less striking p-values (on the
order of 10
 7)—is PJA2, a ubiquitin ligase gene on Chromo-
some 5 [10]; its position marked in Figure 1. This possible
association has not been examined further.
Based on the genetic results, we hypothesized that variants
underlying the association with UA levels affect a critical step
in UA production or elimination. We started to test this
hypothesis by studying the relationship between UA and the
two top strongly associated SNPs in GLUT9 in an independ-
ent population sample. We examined participants in the
InCHIANTI study, an epidemiological study ongoing in two
Italian towns in Chianti, Tuscany. A detailed description of
the study design and data collection methods of the
InCHIANTI study has been published [11,12]. The study
population consists of 1,301 individuals (579 males and 722
females), comprising a random sample of the population aged
65 years and older supplemented with 30 men and 30 women
randomly selected in each decade between ages 20 and 70.
Table 1 and Figure 2 show that the results in this cohort
replicate the ﬁndings in the Sardinian group. For SNP
rs6855911, the allele G has a negative additive effect of 0.39
mg/dl (p ¼ 1.54 3 10
 11). Similarly, the rare allele G for
rs7442295 has a negative additive effect of 0.42 mg/dl (p¼2.57
310
 12). Again, GLUT9 variants signiﬁcantly and comparably
affect UA levels over the whole distribution of values, without
a threshold (Figure 2). Interestingly, while none of the
Sardinian participants had hyperuricemia (UA . 7.5 mg/dl
in men and .6.2 mg/dl in women), in the InCHIANTI study,
participants with at least one G allele had a signiﬁcantly lower
prevalence of hyperuricemia (AA: 11.1%; AG: 7.2%; GG:
3.5%; p ¼ 0.009).
UA levels generally increase with age (e.g., [13]), and the
InCHIANTI cohort is considerably older than the Sardinian
sample, resulting in higher mean values for each genotype
(Figure 2). However, the values for corresponding age groups
in the two are very similar, as are the contribution of the
GLUT9 alleles and the greater effect in females (Figure 2;
Table 1).
Because the Sardinian population, as a founder population,
Figure 1. Genome-Wide Association Scan Results for UA Levels in Sardinian Cohort
Probability of association (plotted as log10) according to their positions along the p to q arms of each chromosome (1 to 22 and X) for each of 362,169
SNPs that passed quality control filters. The highest p-values are at the positions of the GLUT9 and PJA2 genes, and are indicated by vertical dotted lines.
doi:10.1371/journal.pgen.0030194.g001
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Author Summary
High serum uric acid levels lead to gout and increase the risk of
cardiovascular and kidney disease. To determine what genetic
factors might contribute to uric acid levels, we conducted genome-
wide scans of single nucleotide variations in DNA in population
samples from Sardinia and Chianti. We report here that variants in
the GLUT9 gene are associated with altered uric acid levels in both
populations. Unexpectedly, rather than being directly involved in
uric acid synthesis or secretion, the GLUT9 gene encodes a glucose
transporter. It is of interest that the gene is predominantly expressed
in liver, a major site of uric acid synthesis, and in kidney, where uric
acid is excreted and reabsorbed. However, it now remains to be
determined how altered glucose uptake can indirectly affect
synthesis or excretion/reabsorption of uric acid, and whether GLUT9
may provide a target for the therapeutic modification of uric acid
levels.is relatively homogeneous (reviewed in [13]), it can facilitate
the detection of associated SNPs but might emphasize genes
that are important only on the island. In this respect,
mainland Italian residents are both genetically much more
heterogeneous and distinct from Sardinians (as distant from
Sardinians as American Caucasians are [14]). Thus, the
replication of allele effects in Chianti suggests that GLUT9
is involved in a general mechanism of UA production/
elimination that may be biologically important in other
populations as well.
The initial SNPs tested and found associated with UA levels
all fall in noncoding regions. To assess any candidate SNPs in
the coding region and/or promoter of the gene, the exons and
a 1.5 kb presumptive promoter region upstream of the
transcription start site were ampliﬁed by PCR and sequenced
in 30 individuals (ten for each homozygote and ten hetero-
zygotes for rs6855911). The primers used to amplify the genes
are listed in Table S2. The sequencing found no new SNPs.
However, we identiﬁed several SNPs in Sardinian DNA
samples that were previously described in other populations.
They include six SNPs in the promoter region and nine in
exons (results are in Table S3). Among the other SNPs in the
region, rs16890979, a nonsynonymous SNP in exon 8 that
produces a Val253Ile amino acid change, was in strong
linkage disequilibrium with rs6855911 (r
2 ¼ 0.74 in the
HapMap CEU and r
2 ¼ 1.0 among the 30 resequenced
individuals). However, genotyping of that coding SNP in a
further 541 Sardinians suggests that rs6855911 and other
noncoding SNPs in the region are more strongly associated
with UA levels (p , 0.0004 for rs737267 and other noncoding
SNPs in strong linkage disequilibrium with rs6855911, p ¼
0.02 for rs16890979). Further analyses are necessary to
identify the causal variant(s) in the region.
Discussion
How might variants of GLUT9 differentially affect UA
levels? Studies have veriﬁed that GLUT9 transports glucose
[15], and both characterized isoforms, comprising 540 and
511 amino acids [15], respectively, are highly expressed in
liver and distal kidney tubules. In the liver, where much UA is
synthesized, rare deﬁciency of glucose-6-phosphatase (Glyco-
genosis Type I; Online Mendelian Inheritance in Man 232200)
leads to increased levels of UA. Variations in the uptake of
glucose via GLUT9 might also result in increases or decreases
in glucose-6-phosphate and modulate metabolism through
the pentose phosphate shunt. Augmented levels of phosphor-
ibosyl pyrophosphate synthesis, for example, could then lead
to increased hepatic production of UA.
Alternatively, or in addition, the effect of GLUT9 on UA
level may be exerted through effects on renal excretion. In
the kidney, urate transport occurs in the proximal tubular
epithelium, whereas GLUT9 is expressed in more distal
nephron segments, perhaps the distal convoluted or con-
necting tubules [16]. However, those segments are relatively
anaerobic, and one can speculate that the levels of lactate and
other anions could be altered by metabolism from the glucose
supplied by GLUT9, with consequent changes in organic
Table 1. Effect Sizes of Two SNPs in GLUT9 on UA Levels in Sardinian and InCHIANTI Cohorts
SNP Cohort Estimated Additive
Effect
a (G)
Genotype Means (mg/dl)
A/A A/G G/G
rs6855911 SardiNIA All  0.317 4.66 (þ/ 1.51) 4.48 (þ/ 1.59) 4.02 (þ/ 1.63)
Men  0.289 5.55 (þ/ 1.44) 5.38 (þ/ 1.50) 4.85 (þ/ 1.63)
Women  0.359 3.94 (þ/ 1.13) 3.63 (þ/ 1.15) 3.03 (þ/ 0.94)
InCHIANTI All  0.397 5.27 (þ/ 1.44) 4.94 (þ/ 1.31) 4.33 (þ/ 1.37)
Men  0.311 5.75 (þ/ 1.44) 5.45 (þ/ 1.31) 5.09 (þ/ 1.37)
Women  0.490 4.86 (þ/ 1.31) 4.57 (þ/ 1.18) 3.65 (þ/ 0.96)
rs7442295 SardiNIA All  0.331 4.70 (þ/ 1.52) 4.44 (þ/ 1.61) 3.84 (þ/ 1.34)
Men  0.297 5.56 (þ/ 1.42) 5.36 (þ/ 1.55) 4.69 (þ/ 1.08)
Women  0.383 3.97 (þ/ 1.18) 3.56 (þ/ 1.11) 2.95 (þ/ 0.96)
InCHIANTI All  0.427 5.25 (þ/ 1.43) 4.94 (þ/ 1.34) 4.13 (þ/ 1.20)
Men  0.320 5.72 (þ/ 1.43) 5.47 (þ/ 1.36) 4.90 (þ/ 1.12)
Women  0.539 4.86 (þ/ 1.31) 4.52 (þ/ 1.16) 3.40 (þ/ 0.85)
Values are given as mean and standard deviation.
aEffect was estimated in a variance component model including sex, age, age
2 as covariates.
doi:10.1371/journal.pgen.0030194.t001
Figure 2. Boxplot for UA Levels Correlated with rs6855911 Genotypes in
Sardinian and InCHIANTI Population Cohorts
Standard boxplots are drawn with min, 0.25 quantile; median, 0.75
quantile; and 0.75 quantile þ 1.5*IQR for the levels of UA (mg/dl). To
increase readability, outliers were removed from the boxplots, but they
were taken into account when estimating the parameters. Sample size
for each genotype class is also annotated.
doi:10.1371/journal.pgen.0030194.g002
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GLUT9 Associated with Serum Uric Acid Levelsanion concentration in the interstitium and neighboring
proximal tubule cells. Anions are exchanged for urate by the
transporter URAT1, with lactate as a preferred exchange ion
[7], affecting the coupled process whereby ﬁltered urate is
reabsorbed from the urine in exchange for cytosolic organic
anions. Hence, GLUT9 variants in the kidney could change
the ambient level of organic anions and thereby alter urate
reabsorption and circulating urate levels. Effects could be
more marked in individuals with purine-rich diets, or in
hypertensive individuals in whom reabsorption is favored by
reduced blood ﬂow in the proximal tubule [17] and/or
localized ischemia [2].
Regardless of underlying mechanism, GLUT9 variants
clearly have a signiﬁcant modulating effect on levels of UA.
Homozygotes for the two allelic variants differ in serum UA
by 0.6 mg/dl, or on the order of 10% of the mean levels. Based
Figure 3. Association Results and Linkage Disequilibrium Patterns in Region Surrounding the GLUT9 Gene
(A) Summary of the association between SNPs in the region and UA levels. The SNP showing strongest association (rs6855911) is highlighted. Other
SNPs are colored according to their degree of disequilibrium with rs6855911, ranging from high (red), to intermediate (green), to low (blue). Transcripts
in the region are indicated at the bottom of the graph, with an arrow indicating the direction of transcription.
(B) Patterns of linkage disequilibrium in the region in Sardinia and in two of the HapMap populations (CEU and YRI) [25], where r
2 values are calculated
according to [26] and colored as (A). The grey bar marks the region of association and facilitates comparisons between the panels.
doi:10.1371/journal.pgen.0030194.g003
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GLUT9 Associated with Serum Uric Acid Levelson the ﬁndings in an independent study [18], such a
difference in UA levels would change the rate of cardiovas-
cular events by about 1%.
In further assessing the impact of such variation, it is
notable that many authors ([19] and review in [4]) have
pointed out that UA can function as an antioxidant, and that
at earlier times in evolution, this may have been beneﬁcial to
human populations, in fact leading to the inactivation of
uricase. Consistent with a possible need for UA in past
generations, we found that the observed allele associated with
higher levels of UA, AA, is more common on a population
level. Allele GG, which is associated with lower levels, occurs
in only 6.9% of the Sardinian and 6.6 % of the InCHIANTI
population sample (Table S4 gives the absolute numbers).
In those individuals with intermediate levels of UA, it
remains unclear whether it functions simply as an antioxidant
that tends to increase in conditions characterized by tissue
damage or whether it has a deleterious effect; and at very high
levels UA is patently pathological. However, in individuals
with very high levels, UA is patently pathological and
mortality increases [3]. In such individuals, the G allele may
be partially protective, and intriguingly, in the InCHIANTI
study, participants with at least one G allele had a
signiﬁcantly lower prevalence of hyperuricemia (deﬁned as
UA .7.5 mg/dl in men and .6.2 mg/dl in women) compared
to those with only A alleles. It would be of interest to verify
whether variants of associated SNPs in the GLUT9 gene are
less represented in particular groups of individuals with
different clinical forms of hyperuricemia and in sporadic
gout patients. Such effects would support the suggestion that
GLUT9 may eventually provide a target for clinical inter-
vention.
Materials and Methods
Recruitment and UA determinations. We recruited and pheno-
typed 6,148 individuals, male and female, 14–102 y old, from a cluster
of four towns in the Lanusei Valley [13]. Blood samples were collected
in the morning after the participants had been fasting for at least 12 h
and after sitting for 15 min, both for SardiNIA and InCHIANTI
cohorts. Aliquots of serum were immediately obtained and stored at
 80 8C, and were subsequently used for the assessment of UA. UA
(mg/dl) was measured using enzymatic–colorimetric methods (Bayer
for SardiNIA; Roche Diagnostics for INCHIANTI). The lower limits of
detection were 0.2 mg/dl, range 0.2–25.0 mg/dl, intra-assay and inter-
assay coefﬁcients of variation were equal to 0.5% and 1.7%,
respectively. Hyperuricemia was deﬁned as a serum urate concen-
tration .7.5 mg/dl (450 lmol/l) in men and .6.2 mg/dL (372 lmol/l) in
women, in agreement with clinical laboratory standards.
Genotyping. In the Sardinian cohort, 3,329 and 1,412 individuals
were genotyped with the Affymetrix 10K and Affymetrix 500K
Mapping array set, respectively, with 436 individuals generating an
overlapping dataset. We took advantage of the relatedness among
individuals in our sample to reduce study costs. Using a modiﬁed
Lander-Green algorithm, full genotypes on the 2,893 individuals
typed with only the 10K panel were imputed based on stretches of
shared haplotype, permitting analyses on 4,305 individuals [20].
For genotyping for replication in the InCHIANTI cohort, allelic
discrimination assays with predeveloped assay reagents (Applied
Biosystems) for SNPs rs6855911 and rs7442295 were carried out using
an ABI 7900HT sequencer detector system. Each 10 ll reaction
volume was prepared according to manufacturer’s directions, and
contained 5 ll of twice-concentrated TaqMan Universal PCR master
mix, 0.25 ll of 40-fold concentrated SNP genotyping assay mix with
amplifying primers and oligonucleotide labeled with VIC or FAM
reporter dyes for the corresponding alleles, 1 ll containing 5 ng of
template DNA from an InCHIANTI subject, and 3.75 ll of water.
Assays were run in 96-well format. Controls included DNA with
sequence-veriﬁed homozygous alleles, DNA with heterozygous alleles,
or no template DNA, in each assay plate. Following allele discrim-
ination assays, a total of 14 random samples representing each allelic
state were also checked by direct sequencing, conﬁrming allele calls
in all cases.
Statistical analyses. Analyses in the Sardinia cohort were carried
out as in [20]. We focused on 362,129 SNPs that passed quality control
checks. We used a linear regression model to estimate the association
between each SNP and UA levels. To avoid inﬂated type I error rates
due to the departure from normality of measured UA levels, we
applied an inverse normal transformation to the phenotype prior to
analysis. We used an additive model and included sex, age, and age
2 as
covariates.
For individuals who had genotype data available at the SNP being
tested, we coded genotypes as 0, 1, or 2, depending on the number of
copies of an arbitrary reference allele for each SNP. For individuals
with missing genotype data, we used the Lander-Green algorithm to
estimate the number of copies of the allele carried by each individual
(based on the genotypes of family members) and assigned each
individual a score ranging between 0 and 2 [21]. This estimate
incorporates allele frequency information, the genotypes of relatives
for the SNP of interest, and ﬂanking marker data. For computational
efﬁciency, the Lander-Green algorithm was applied to sub-pedigrees,
each including no more than 20–25 individuals, resulting in a dataset
where the average analysis unit consisted of a family with 12.3
members and 3.2 generations. Finally, we used a variance component
approach to account for correlation between different observed
phenotypes within each family [21]. To evaluate association on the X
chromosome, we modeled a polygenic variance component shared
according to an X-linked kinship coefﬁcient in addition to the usual
autosomal polygenic variance component [13,21]. Further, we
assumed that average phenotypic values for hemizygous males would
be the same as for homozygous females [13,21].
Analysis for replication in the InCHIANTI population was carried
out by again coding genotypes as 0, 1, or 2 and ﬁtting a linear
regression model adjusting for sex, age, and age
2.
For the sequential analysis, the best SNP for each trait was selected
ﬁrst, and the analysis was conditioned on it to select successively the
next best SNP. To carry out this conditioning, we simply added the
best SNP as a covariate to the model and repeated the genome-wide
association scan for all other SNPs. The same process was repeated in
Table 2. Association Signals Identified in a Sequential Analysis
Round Marker Chromosome Position Allele Effect H2 p-Value
1 rs6855911 4 9612179 A 0.236 3.49% 1.80e 16
2 rs717614 4 9781057 G 0.099 0.76% 3.30e 07
3 rs17057956 18 71586047 A  0.360 1.03% 1.90e 06
4 rs784291 5 108694666 C 0.114 1.09% 1.40e 06
5 rs875530 18 7764104 C 0.101 0.86% 1.30e 05
Summary of an analysis in which all SNPs in the genome were evaluated in turn. After identifying the ‘‘best’’ SNP, its corresponding allele count was incorporated in the association model
and the genome-wide scan was repeated to identify the second best SNP. The procedure was repeated for five rounds (see Materials and Methods). For each SNP, the round in which it
was selected is listed, followed by the chromosome and corresponding position. The allele tested is listed together with its impact on the trait (in standard deviation units for the
transformed phenotype), the proportion of variance it explains, and the p-value for a test evaluating significance of the observed association.
doi:10.1371/journal.pgen.0030194.t002
PLoS Genetics | www.plosgenetics.org November 2007 | Volume 3 | Issue 11 | e194 2160
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with multiple independent association signals. After ﬁve rounds,
additional SNPs identiﬁed had p-values that were far less signiﬁcant.
Sequencing of exons and putative promoter regions with SNP
variants. Oligonucleotide primers to amplify putative promoter
regions and exons, including the splice sites for two isoforms of the
GLUT9 gene, were designed based on the exon–intron borders
represented in the University of California Santa Cruz (UCSC)
genome assembly [22] using the primer prediction program Primer3
[23] interfaced with the UCSC genome browser. In the putative
promoter regions, repeats were masked by Repeat Masker [24], and
only primers outside the repeats were selected. A list of primers used
to amplify the exons is given in Table S2.
The exons were ampliﬁed by PCR in 25 ll reactions containing 0.2
mM dNTPs, ﬁnal concentration 1 lM each of forward and reverse
primers, 2 mM MgCl2, and 50 ng of genomic DNA as template, with 1
unit recombinant Taq DNA polymerase (Invitrogen). The cycling
conditions were as follows: 95 8C 5 min, followed by 95 8C for 30 sec,
60 8C for 30 sec, and 72 8C for 30 sec for 30 cycles. The PCR products
were puriﬁed by using ExoSAP-IT (USB Corporation) and were
sequenced bidirectionally using the ABI PRISM BigDye Terminator
v3.1 Cycle Sequencing Kit according to the manufacturer’s recom-
mendations, on an ABI PRISM 3100 Sequencer, and visualized with
DNA Genetic Analyzer software (ABI PRISM 3100 Genetic Analyzer).
Supporting Information
Table S1. SNPs with Genome-Wide p-Value ,10
 6 for an Effect on
UA Level in the Sardinian Cohort
The 40 SNPs all fall in or very near the GLUT9 gene; positions of the
sequences are according to UCSC [22], March 2006 genome build.
Found at doi:10.1371/journal.pgen.0030194.st001 (62 KB DOC).
Table S2. Primers Used to Amplify Each Exon and Putative Promoter
Region of GLUT9
Forward and reverse primers are listed for exons and a 1.5 kb
putative promoter regions of the GLUT9 isoform 2. Positions along
the gene are according to UCSC [22] March 2006 genome build.
Dashes indicate exons with no polymorphic SNPs in the database.
Found at doi:10.1371/journal.pgen.0030194.st002 (30 KB DOC).
Table S3. Sequence Variants in GLUT9 Putative Promoter, Exons, and
Introns in Sardinian Individuals with Alternative Genotypes for SNP
rs6855911
DNA segments from ten individuals homozygous for the minor allele
(GG), the major allele (AA), or heterozygous (AG) for rs6855911 were
ampliﬁed by PCR and sequenced. For each individual, using primers
listed in Table S1, sequence was determined for 1.5 kb putative
promoter region for isoform 2, exons, and intron/exon boundaries of
GLUT9. SNPs [25] with the indicated identiﬁcation numbers were
found in the samples, and genotypes are shown for each. An asterisk
marks the strongest candidate for association. SNPs in putative
promoter regions and exons are as in Table S1. SNP rs3733589 in
exon 4 was monomorphic in the samples tested (unpublished data).
Amino acid positions in the protein refer to protein accession
number NP001001290. The Gly 25 Arg change is speciﬁc to GLUT9
isoform I (NP064425). nd, allelic calls not determined
Found at doi:10.1371/journal.pgen.0030194.st003 (67 KB DOC).
Table S4. Numbers of Individuals with Each Genotype for Two SNPs
in Sardinia and InCHIANTI Population Cohorts
Found at doi:10.1371/journal.pgen.0030194.st004 (26 KB DOC).
Accession Numbers
The National Center for Biotechnology Information (NCBI) Online
Mendelian Inheritance in Man (OMIM, http://www.ncbi.nlm.nih.gov/
entrez/dispomim.cgi?id¼232200) accession number for Glycogen
storage disease Ia, simulating primary gout and xanthomatosis, is
MIM 232200.
The NCBI Entrez database (http://www.ncbi.nlm.nih.gov/sites/
gquery) accession number for Solute carrier family 2, member 9
protein isoform I, is NP 064425.
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